Chemomab Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Chemomab Therapeutics (CMMB).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$27Upside to Avg. PT+2042.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2025	Oppenheimer	Jeff Jones	PT Raise	Outperform	$10→$25
May 16, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$11→$10
Feb 20, 2025	Maxim Group	Michael Okunewitch	PT Raise	Buy	$4→$7
Nov 15, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$13→$11
May 13, 2024	Maxim Group	Michael Okunewitch	Initiate	Buy	$4
May 6, 2024	Oppenheimer	Jeff Jones	Upgrade	Perform→Outperform	$6
Mar 8, 2024	Oppenheimer	Jeff Jones	Maintained	Perform	—
Dec 19, 2023	Roth MKM	Dylan Dupuis	Reinstates	Buy	$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and raises the price target from $10 to $25.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and lowers the price target from $11 to $10.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

Maxim Group analyst Michael Okunewitch maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and raises the price target from $4 to $7.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

Oppenheimer analyst Jeff Jones reiterates Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and lowers the price target from $13 to $11.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target

Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Outperform and announces $6 price target.

Benzinga Newsdesk

Chemomab Therapeutics Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

Chemomab Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

PRO
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

PRO
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

PRO
Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

PRO
Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target

People Also Watch

People Also Watch

Chemomab Therapeutics Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

Chemomab Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

PROOppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

PROMaxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

PROOppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

PROMaxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

PROOppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target

People Also Watch

People Also Watch

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

PRO
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Lowers Price Target to $10

PRO
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

PRO
Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

PRO
Maxim Group Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $4

PRO
Oppenheimer Upgrades Chemomab Therapeutics to Outperform, Announces $6 Price Target